Skip to main content

Psyence Biomedical Ltd.

corporate_fare Company Profile

Psyence Biomedical Ltd.

PBM·NASDAQ·Life Sciences·CIK 0001985062

PSYENCE BIOMEDICAL LTD. is a company that engages in clinical research, specifically managing a Phase IIb Study through its wholly-owned subsidiary, Psyence Australia. On May 21, 2025, Psyence Australia entered into a Master Services Agreement (MSA) with Southern Star Research, which will act as the Contract Research Organization (CRO) for the Company's registrational Phase IIb Study. Southern Star Research will provide a range of CRO services, including Trial Management & Oversight, which covers clinical monitoring, site initiation, site management, and close-out activities. They will also handle Project Management, involving the development and maintenance of a detailed project plan, coordination of teams, and status reporting. Data Management & Biostatistics services include designing, building, and maintaining the electronic data capture (EDC) system, data cleaning, database lock, and generating statistical reports. Regulatory & Ethics Support involves preparing submissions to the Therapeutic Goods Administration (TGA) in Australia and local ethics committees, as well as managing regulatory correspondence. Pharmacovigilance & Safety Oversight includes collecting, processing, and reporting adverse events. Patient Recruitment & Retention assistance will focus on site selection, patient screening, and retention programs to enroll the target 87 participants in the double-blind, placebo-controlled study. Finally, Transitional Handover will coordinate with the Company's prior CRO, iNGEN, for a seamless transition. The Company will pay Southern Star Research aggregate fees, structured as an upfront deposit (a percentage of total project costs) and monthly invoices for services delivered, plus reimbursement for out-of-pocket costs.

Psyence Biomedical Ltd. (NASDAQ:PBM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PBM at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Psyence Biomedical Finalizes 1-for-6.25 Reverse Stock Split Effective February 2nd After Delay
  • Psyence Biomedical Adjourns Shareholder Meeting Due to Lack of Quorum
  • Psyence Biomedical Announces Second Reverse Stock Split to Maintain Nasdaq Listing
  • Activist Investor KAOS Capital Reiterates Concerns, Seeks Board Changes at Psyence Biomedical
  • Psyence Biomedical to Vote on Proposed Share Consolidation at Upcoming Meeting

Financial Snapshot

Fiscal year ended March 31, 2026
Net Income
-$6.94M
Diluted EPS
-$12.56
Op. Cash Flow
-$8.14M
Free Cash Flow
-$8.14M
Cash & Equivalents
$7.44M
Debt / Equity
0.00×
Shares Outstanding
2.44K sh
Source: 20-F · filed 2026-06-22 · accession 0001213900-26-070607

Insider Transactions

PBM files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$3.01 +1.19% today
52-week range · as of 2026-11-19 $1.92 – $18.31
Market cap
$15.8M
Volume
32.7K (0.6× avg)
3-mo avg 50.8K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PBM - Filings & News (Page 2)

PBM
Jan 29, 2026, 6:10 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.738
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $15.795M info
PBM
Jan 27, 2026, 6:03 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6305
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $15.795M info
PBM
Jan 14, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $0.7628
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $15.795M info
PBM
Jan 13, 2026, 6:17 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.7825
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $15.795M info
PBM
Jan 12, 2026, 8:53 PM EST
Filing Type: 6-K/A
Importance Score:
7
Price at Filing: $0.8217
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $15.795M info
PBM
Jan 08, 2026, 4:06 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.7682
Real-time Price: $3.01 info
Change: Reverse Stock Split info
Market Cap: $15.795M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets